Roche Holding AG (RHHVF)
Roche Holding AG
Konzern Hauptsitz
Grenzacherstrasse 124
Basel 4070
Switzerland
41 61 688 11 11
https://www.roche.com
版塊: Healthcare
行業: Drug Manufacturers—General
全職員工: 100,920
高階主管
| 名稱 | 標題 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Severin Schwan Ph.D. | CEO & Exec. Director | 7.66M | 無 | 1967 |
| Dr. Alan Hippe | Chief Financial & Information Officer | 4.39M | 無 | 1967 |
| Ms. Cristina A. Wilbur | Chief People Officer | 3.14M | 無 | 1967 |
| Dr. Johannes Carolus Clevers M.D., Ph.D. | Head of Roche Pharma Research & Early Devel. | 356.52k | 無 | 1957 |
| Dr. Thomas Schinecker | Chief Exec. Officer of Roche Diagnostics | 3.01M | 無 | 1975 |
| Mr. William N. Anderson | Chief Exec. Officer of Roche Pharmaceuticals | 6.61M | 無 | 1966 |
| Dr. Bruno Eschli | Head of Investor Relations | 無 | 無 | 無 |
| Ms. Claudia Bockstiegel | Gen. Counsel | 無 | 無 | 1964 |
| Ms. Pascale Schmidt | Chief Compliance Officer | 無 | 無 | 1973 |
| Ms. Barbara Schadler | Head of Group Communications | 無 | 無 | 1962 |
描述
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
公司管治
截至 2022年9月1日 止，Roche Holding AG 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：10；董事會：6；股東權利：1；現金賠償：8。
